Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Core Laboratories Inc (NYSE: CLB) closed at $13.81 down -0.93% from its previous closing price of $13.94. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
For a deeper understanding of Core Laboratories Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 33.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.12. For the most recent quarter (mrq), Quick Ratio is recorded 1.71 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.71 whereas as Long-Term Debt/Eq ratio is at 0.67.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Citigroup on June 30, 2023, Downgraded its rating to Sell and sets its target price to $21 from $22 previously.
On April 18, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $21.50.
Valuation Measures:
As of this moment, Core’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.01, and their Forward P/E ratio for the next fiscal year is 12.84. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.23 while its Price-to-Book (P/B) ratio in mrq is 2.57.
Stock Price History:
Over the past 52 weeks, CLB has reached a high of $25.13, while it has fallen to a 52-week low of $13.70. The 50-Day Moving Average of the stock is -20.94%, while the 200-Day Moving Average is calculated to be -27.53%.
Shares Statistics:
A total of 46.83M shares are outstanding, with a floating share count of 46.35M. Insiders hold about 1.01% of the company’s shares, while institutions hold 109.26% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is $0.23, with high estimates of $0.27 and low estimates of $0.19.
Analysts are recommending an EPS of between $1.11 and $0.8 for the fiscal current year, implying an average EPS of $0.91. EPS for the following year is $1.0, with 2.0 analysts recommending between $1.05 and $0.95.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $126.81M this quarter.It ranges from a high estimate of $131.53M to a low estimate of $123.8M. As of the current estimate, Core Laboratories Inc’s year-ago sales were $129.64MFor the next quarter, 3 analysts are estimating revenue of $131.64M. There is a high estimate of $136.31M for the next quarter, whereas the lowest estimate is $128.4M.
A total of 4 analysts have provided revenue estimates for CLB’s current fiscal year. The highest revenue estimate was $568.2M, while the lowest revenue estimate was $520.6M, resulting in an average revenue estimate of $542.73M. In the same quarter a year ago, actual revenue was $523.85MBased on 3 analysts’ estimates, the company’s revenue will be $560.49M in the next fiscal year. The high estimate is $580M and the low estimate is $546.6M.
